Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 22, 2013 (14 years ago)

Diclofenac Sodium and Misoprostol Delayed-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specifications: Broken tablets

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Diclofenac Sodium and Misoprostol Delayed-Release Tablets, 75mg/0.2mg, Rx only, Manufactured by Watson Laboratories, Inc., Corona, CA 92880, NDC 0591-0398-60 (60 count bottles)

Affected NDC 0591-0398-60

Compare with the code on your package — it is the most precise check available.

Drug: Diclofenac Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Diclofenac Sodium and Misoprostol
NDC 00591-0398
DICLOFENAC SODIUM 75 mg/1; MISOPROSTOL 200 ug/1 Tablet, Delayed Release
Oral
Actavis Pharma, Inc. Rx
Recalling firm
Actavis Inc
NDC code
0591-0398-60
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1060-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Diclofenac recalls

See all
Class II · Moderate risk

Diclofenac Sodium

Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

Ongoing Failed specification Sun Pharmaceutical Industries INC NDC 51672-1363-7 D-0342-2026
Class II · Moderate risk

Diclofenac Sodium Topical Solution 1.5% w/w

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Terminated Stability / shelf life Preferred Pharmaceuticals, Inc. NDC 68788-7918-01 D-0773-2022

Other recalls by Actavis Inc

All 2013 recalls
Class III · Low risk

Levofloxacin Ophthalmic Solution

Failed Impurities/ Degradation Specifications: OOS for related compound (levofloxacin n-oxide) at the 18 month stability time point.

Terminated Impurity / degradation Actavis Inc NDC 50383-283-05 D-0514-2017
Class II · Moderate risk

Glipizide extended-release tablets

Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

Terminated Dissolution failure Actavis Inc NDC 0591-0900-30 D-0476-2017
Class III · Low risk

Hydrocortisone and acetic acid otic solution

Failed Impurities/Degradation Specifications: Out of specification (OOS) results for related compound G were obtained at 12-month (at expiry) stability time-point for room temperature sample(s).

Terminated Impurity / degradation Actavis Inc NDC 45963-412-61 D-1472-2016